Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Saved in:
Bibliographic Details
Title: Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Authors: Weinstock-Guttman B; Jacobs Neurological Institute, Buffalo, NY 14203-1126, USA. bguttman@thejni.org, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C
Source: Journal of neurology [J Neurol] 2012 May; Vol. 259 (5), pp. 898-905. Date of Electronic Publication: 2011 Oct 19.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-1459
DOI:10.1007/s00415-011-6275-7